| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 02/10/2005 | WO2005011725A2 Anti-angiogenetic agent and its use, in particular in cancer treatment |
| 02/10/2005 | WO2005011686A1 2-imino-4-(thio) oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors |
| 02/10/2005 | WO2005011679A1 Thio-substituted phenbutazone compounds as anti-inflammatory, anti-viral and immunomodulatory agents |
| 02/10/2005 | WO2004110979A3 Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator |
| 02/10/2005 | WO2004103401A3 Avian combination-vaccine against e.coli and salmonella |
| 02/10/2005 | WO2004093903A3 Methods and compositions for immunomodulation using cd1 antigens |
| 02/10/2005 | WO2003086175A8 Compositions and methods for the therapy and diagnosis of lung cancer |
| 02/10/2005 | WO2003050295A3 Assays and implements for determining and modulating hsp90 binding activity |
| 02/10/2005 | US20050034179 Transgenic animal cell which express tumor necrosis factor receptor for use in identifying agents for treatment of diabetes and inflammatory bowel disease |
| 02/10/2005 | US20050033414 Drug-eluting stent with multi-layer coatings |
| 02/10/2005 | US20050033066 Pkb-3564 substance with neovascularization inhibitory activity |
| 02/10/2005 | US20050033055 Edg receptor agonists |
| 02/10/2005 | US20050033028 Reducing immunogenicities of immunoglobulins by framework-patching |
| 02/10/2005 | US20050033018 Receptors and membrane-associated proteins |
| 02/10/2005 | US20050033017 Nucleotide sequences coding receptor for advanced glycation endproducts (RAGE) for identifying modulators for treatment and prevention of cell proliferative and cardiovascular disorders |
| 02/10/2005 | US20050032858 Novel heterocyclic compound and anti-inflamatory agent |
| 02/10/2005 | US20050032851 E. g.,N-[[4-[2-(5-Methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl]sulfonyl]acetamide; side effect reduction; non-steroidal antiinflammatory agents; antiarthritic agents; analgesics; antipyretics; acylation of the corresponding sulfoamide by an anhydride a solvent and base |
| 02/10/2005 | US20050032838 Nicotinamide derivatives useful as PDE4 inhibitors |
| 02/10/2005 | US20050032830 Ether substituted imidazopyridines |
| 02/10/2005 | US20050032826 Medical devices containing rapamycin analogs |
| 02/10/2005 | US20050032825 rapamaycin derivatives used as fungicides, anticarcinogenic agents, immunosuppressants or as coatings on drug eluting stents to prevent restenosis |
| 02/10/2005 | US20050032816 N-oxide anthranylamide derivatives and their use as medicaments |
| 02/10/2005 | US20050032808 Pyrazine carboxamide compounds for use in treatment of obesity, psychiatric and neurological disorders; for example, N-(1-piperidinyl)-5,6-diphenyl-2-pyrazinecarboxamide |
| 02/10/2005 | US20050032792 Peptidyl spiroheterocyclic, amidino and guanidino compounds; reversible inhibitors of the cysteine protease cathepsin S, K, F, L and B; useful in the treatment of autoimmune and other related diseases |
| 02/10/2005 | US20050032779 enzyme inhibitors such as 2-[4-(4-Dimethylaminophenyl)piperazin-1-yl]4,5-dihydroimidazo[4,5,1-ij]quinolin-6-one, used for treating or preventing disorders in which poly/ADP-ribose/ polymerase is involved |
| 02/10/2005 | US20050032772 Compounds useful as reversible inhibitors of cysteine proteases |
| 02/10/2005 | US20050032742 Chemo-enzymatic synthesis of sialylated oligosaccharides |
| 02/10/2005 | US20050032736 Immunostimulatory nucleic acid molecules |
| 02/10/2005 | US20050032723 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals |
| 02/10/2005 | US20050032715 Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds |
| 02/10/2005 | US20050032704 Neural thread proteins (NTP); antiproliferative agents |
| 02/10/2005 | US20050032686 administering to a manimal a therapeutically effective amount of ES-62 ( a glycoprotein) to treat an inflammatory disease: arthritis and chronic obstructive pulmonary disease |
| 02/10/2005 | US20050032207 Method for isolating, culturing and differentiating intestinal stem cells for therapeutic use |
| 02/10/2005 | US20050032062 Methods for the assessment and prognosis of sarcoidosis |
| 02/10/2005 | US20050031709 Butyrospermum-triterpene fraction containing lupeol; alpha -amyrin and/or beta amyrin, and butyrospermol; plant extract |
| 02/10/2005 | US20050031646 Immunogens; polysaccharide conjugate antigens derived from pathogenic bacterium conjugated to protein D from Haemophilus influenzae |
| 02/10/2005 | US20050031635 Inducing specific B cell anergy to an immunogen comprising a conjugate of a nonimmunogenic valency platform molecule and an analog of the immunogen that (a) binds specifically to B cells to which the immunogen binds and (b) lacks the T cell epitope(s) of the immunogen |
| 02/10/2005 | US20050031613 CD 16 antigen; antibody produced by cell unresistant to lectin which recognizes sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through alpha -bond in a complex N-glycoside-linked sugar chain; signal transduction |
| 02/10/2005 | US20050031609 Compositions for use in treating ige-associated disorders |
| 02/10/2005 | US20050031601 Composition comprising a lactobacillus pentosus strain and uses thereof |
| 02/10/2005 | US20050031583 Uses of opg to modulate immune responses |
| 02/10/2005 | US20050031577 Therapeutic polyesters and polyamides |
| 02/10/2005 | US20050029705 Extrusion die |
| 02/10/2005 | CA2534711A1 Combination therapies for multiple sclerosis |
| 02/10/2005 | CA2534214A1 Treatment of ocular disease |
| 02/10/2005 | CA2533918A1 Use of adcc-optimized antibodies for treating weak patients |
| 02/10/2005 | CA2533600A1 Quantitative method for detecting yessotoxins in fish products based on the activation caused by the toxin in cellular phosphodiesterase and therapeutic usefulness of said activation |
| 02/10/2005 | CA2533506A1 Thio-substituted phenbutazone compounds as anti-inflammatory, anti-viral and immunomodulatory agents |
| 02/10/2005 | CA2532965A1 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
| 02/10/2005 | CA2532870A1 Use of soluble cd164 in inflammatory and/or autoimmune disorders |
| 02/10/2005 | CA2531140A1 2-imino-4-(thio) oxo-5-polycyclovinylazolines for use as pi3 kinase inhibitors |
| 02/09/2005 | EP1505148A1 Methods of screening for agonistic antibodies |
| 02/09/2005 | EP1505075A1 Antibody to human insulin-like growth factor |
| 02/09/2005 | EP1505067A1 4,4-disubstituted piperidine derivatives having ccr3 antagonism |
| 02/09/2005 | EP1505066A1 Polymorph of acid 4-[2-[4-[1-(2-ethoxyethyl)-1h-benzimidazole-2-il]-1-piperidinyl]ethyl]-alpha, alpha-dimethyl-benzeneacetic |
| 02/09/2005 | EP1505061A1 Compound exhibiting pgd 2 receptor antagonism |
| 02/09/2005 | EP1504107A1 Recombinant fowlpox virus |
| 02/09/2005 | EP1504089A2 Allergen mutants |
| 02/09/2005 | EP1504027A2 Adipocyte complement related protein zacrp8 |
| 02/09/2005 | EP1504008A1 7-aminoimidazotriazones |
| 02/09/2005 | EP1503996A1 Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors |
| 02/09/2005 | EP1503992A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors |
| 02/09/2005 | EP1503988A2 Fredericamycin derivatives |
| 02/09/2005 | EP1503800A1 Treatment and prevention of tissue damage |
| 02/09/2005 | EP1503795A2 Use of heat shock proteins to enhance efficacy of antibody therapeutics |
| 02/09/2005 | EP1503794A1 Methods of treatement using ctla-4 antibodies |
| 02/09/2005 | EP1503793A2 Cancer vaccines and methods of using the same |
| 02/09/2005 | EP1503791A2 Methods of therapy for inducing tolerance |
| 02/09/2005 | EP1503786A2 A method of inhibiting the emigration of cells from the intravascular compartment into tissues |
| 02/09/2005 | EP1503785A2 Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants |
| 02/09/2005 | EP1503779A2 Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 02/09/2005 | EP1503778A2 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent |
| 02/09/2005 | EP1503773A1 Hepatoprotective activity of 2 -p-hydroxybenzoylmussaenosidic acid |
| 02/09/2005 | EP1503767A2 Compositions and methods for treatment of vitamin d deficiency |
| 02/09/2005 | EP1503751A1 Therapeutic methods and compositions involving isoflav-3-ene and isoflavan structures |
| 02/09/2005 | EP1503749A2 Methionine aminopeptidase-2 inhibitors and methods of use thereof |
| 02/09/2005 | EP1436252A4 Hydroxyfattysulfonic acid analogs |
| 02/09/2005 | EP1432436A4 Nutrient therapy for immuno-compromised patients |
| 02/09/2005 | EP1423132A4 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 02/09/2005 | EP1210119B1 Pharmaceutical compositions for oral and topical administration |
| 02/09/2005 | EP1150960B1 Polymorphic crystalline forms of celecoxib |
| 02/09/2005 | EP1140939B1 Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-alpha]pyrimidines, and related pharmaceutical compositions and methods |
| 02/09/2005 | EP1087951B1 Carbon substituted aminothiazole inhibitors of cyclin dependent kinases |
| 02/09/2005 | EP1079813B1 Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
| 02/09/2005 | EP1042316B1 Indole derivatives useful a.o. for the treatment of osteoporosis |
| 02/09/2005 | EP0966301B1 Identification of human cytomegalovirus genes involved in down-regulation of mhc class i heavy chain expression |
| 02/09/2005 | EP0700438B1 Opioid receptors: compositions and methods |
| 02/09/2005 | EP0383799B2 Adheson variants |
| 02/09/2005 | CN1578838A Method and means for producing protein with prospective post-translation modification |
| 02/09/2005 | CN1578786A Linear basic compounds having nk-2 antagonist activity and formulations thereof |
| 02/09/2005 | CN1578785A Novel immunogenic compositions for the prevention and treatment of meningococcal disease |
| 02/09/2005 | CN1578781A 1, 8 naphthyridine derivatives and their use to treat diabetes and related disorders |
| 02/09/2005 | CN1578780A 1, 6-naphthyridine derivatives as antidiabetics and pharmaceutical compositions containing them |
| 02/09/2005 | CN1578678A Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
| 02/09/2005 | CN1578672A Rsv基因表达疫苗 Rsv gene expression vaccine |
| 02/09/2005 | CN1578667A Anticancer compositions |
| 02/09/2005 | CN1578665A Type 4 phosphodiesterase inhibitors and uses thereof |
| 02/09/2005 | CN1578661A Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors |
| 02/09/2005 | CN1576281A Viral clearance process |
| 02/09/2005 | CN1188528C Intercellular adhesion molecule-3 and its binding ligands |